Follow The Filings

VIVS VivoSim Labs

VivoSim Labs earnings company data as of 7:50 PM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by VIVS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All VIVS insider trades
  • $2,804 bought by 1 insider
  • $7,300 sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Tony Serge Lialin Chief Commercial Officer
    Buy
    $2,804 10,000 shares at $0.2800 New stake
    Traded Aug 31 Filed Sep 1
    ↗
  2. David Gobel Director
    Sale
    $7,300 3,266 shares at $2.24 100% of stake
    Traded Nov 17, 2025 Filed Nov 19, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 5 stock grants.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 1.01,9.01 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
DEF 14A Filing Doc
8-K 3.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
S-1 Filing Doc
8-K 5.08,8.01,9.01 Filing Doc
8-K 3.01,8.01,9.01 Filing Doc
8-K 1.01,3.02,8.01,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G — Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
424B4 PROSPECTUS Filing Doc
S-1/A AMENDMENT NO. 1 TO FORM S-1 Filing Doc
S-1 REGISTRATION STATEMENT Filing Doc
10-Q Filing Doc
8-K 5.07,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
10-Q Filing Doc
10-K/A Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.